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INTRODUCTION {#sec1-1}
============

Gastroesophageal reflux disease (GERD) is a major health problem in the United States with a prevalence of 5--7% in the general population and an increasing incidence rate (Serag, [2006](#bib51){ref-type="ref"}). Approximately 10% of patients with chronic GERD develop a metaplastic condition known as Barrett\'s esophagus (BE) in which the normal squamous epithelium of the esophagus is replaced by a columnar epithelium with goblet cells. BE is a serious premalignant lesion that can ultimately progress from metaplasia to dysplasia and subsequently to Barrett\'s adenocarcinoma (BA) (Ferraris et al., [1997](#bib19){ref-type="ref"}; O\'Connor et al., [1999](#bib42){ref-type="ref"}; Rana and Johnston, [2000](#bib47){ref-type="ref"}). The incidence of BA has rapidly increased in the Western world over the past three decades (Hamilton et al., [1988](#bib21){ref-type="ref"}; Phillips et al., [1991](#bib46){ref-type="ref"}; Blot et al., [1993](#bib6){ref-type="ref"}), and is comprised of aneuploid tumors characterized by complex molecular alterations (El‐Rifai et al., [2001](#bib17){ref-type="ref"}; El‐Rifai and Powell, [2002](#bib15){ref-type="ref"}). Several genetic abnormalities have been associated with Barrett\'s tumorigenesis, including microsatellite instability (Meltzer et al., [1994](#bib36){ref-type="ref"}), loss of heterozygosity (Dolan et al., [1999](#bib13){ref-type="ref"}), gene‐promoter hypermethylation (Sato and Meltzer, [2006](#bib50){ref-type="ref"}), as well as up‐ and down‐regulation of various genes (Wu et al., [1993](#bib62){ref-type="ref"}; Swami et al., [1995](#bib55){ref-type="ref"}; Regalado et al., [1998](#bib48){ref-type="ref"}; Brabender et al., [2002](#bib7){ref-type="ref"}). Comprehensive molecular analyses of DNA amplifications and gene expression have revealed complex genetic alterations in gastroesophageal and lower esophageal adenocarcinomas (El‐Rifai et al., [1998](#bib16){ref-type="ref"}; Varis et al., [2002](#bib57){ref-type="ref"}; van Dekken et al., [2004](#bib56){ref-type="ref"}; Kuwano et al., [2005](#bib29){ref-type="ref"}).

Analyses of the human transcriptome map of normal tissues have shown clustering of highly expressed genes in chromosomal domains (Caron et al., [2001](#bib9){ref-type="ref"}). Chromosomal arms and bands are known to occupy specific locations within the nucleus known as chromosome territories (CTs). The positioning of a gene(s) can influence its access to the machinery responsible for specific nuclear functions such as transcription and splicing (Cremer and Cremer, [2001](#bib11){ref-type="ref"}). Recently, a few reports have suggested the presence of transcriptional hot spots in the cancer genome, (Wu et al., [2006](#bib63){ref-type="ref"}) where overexpressed genes tend to cluster in defined chromosomal domains; however, similar information remains lacking for most cancer types. Serial analysis of gene expression (SAGE) provides unlimited, comprehensive, genome‐wide analysis of gene expression in a given cell population (Velculescu et al., [1995](#bib58){ref-type="ref"}, [2000](#bib59){ref-type="ref"}). The major advantage in using SAGE is the quantitative ability to accurately evaluate transcript numbers without prior sequencing information. This method has proven invaluable in studies of several tumor types, including adenocarcinomas of the colon (Parle‐McDermott et al., [2000](#bib44){ref-type="ref"}; St Croix et al., [2000](#bib54){ref-type="ref"}), prostate (Culp et al., [2001](#bib12){ref-type="ref"}), pancreas (Argani et al., [2001](#bib1){ref-type="ref"}), ovary (Hough et al., [2000](#bib24){ref-type="ref"}), and breast (Seth et al., [2002](#bib52){ref-type="ref"}). In this study, we explored the BA transcriptome using SAGE and mapped gene‐expression changes to chromosomal positions, thereby generating a map of transcriptional oncogenomic hot spots of this deadly cancer.

MATERIALS AND METHODS {#sec1-2}
=====================

Serial Analyses of Gene Expression {#sec2-1}
----------------------------------

High‐quality total RNA (500 μg) was extracted from four intestinal‐type, moderately to poorly differentiated, BA cases (three gastroesophageal junctional \[GEJ\] and one lower esophageal) using an RNeasy kit (QIAGEN, Hilden, Germany). In addition, four normal gastric mucosa pools were used as reference samples. Each of these pools consisted of four normal gastric mucosal biopsy samples from four different individuals. The tumors selected for SAGE analysis were estimated to consist of more than 70% tumor cells. All normal samples had histologically normal mucosae confirmed on review of hematoxylin‐ and eosin‐stained sections. Importantly, histopathological examination confirmed that none of the normal samples had any areas of inflammation or necrosis. All samples were collected with consent in accordance with approved Institutional Review Board protocols. SAGE libraries were constructed using *Nla*III as the anchoring enzyme and *Bsm*FI as the tagging enzyme as described in SAGE protocol version 1.0e, June 23, 2000, which includes a few modifications of the standard protocol (Velculescu et al., [1995](#bib58){ref-type="ref"}). A detailed protocol and schematic of the method is available at (<http://http://www.sagenet.org/protocol/index.htm>). We sequenced 20,000 clones with an average of 2,500 clones per library, using the Cancer Genome Anatomy Project (CGAP). eSAGE 1.2a software was used to extract SAGE tags, remove duplicate ditags, tabulate tag contents, and link SAGE tags in the database to UniGene clusters using the recently reported ehm‐Tag‐Mapping method (Margulies and Innis, [2000](#bib32){ref-type="ref"}; Margulies et al., [2001](#bib33){ref-type="ref"}). The resulting libraries\' tags were compared with UniGene clusters and the SAGE tag "reliable" mapping database (<http://www.sagenet.org/resources/genemaps.htm>). Statistical analyses of these tags were then performed using eSAGE software.

Quantitative Real‐Time Reverse‐Transcription PCR {#sec2-2}
------------------------------------------------

Quantitative real‐time reverse‐transcription PCR (qRT‐PCR) was performed on 31 adenocarcinomas of Barrett\'s‐related origin, 26 normal gastric epithelial tissues, and 6 Barrett\'s metaplasia tissue samples. All tissues were dissected to obtain ≥70% cell purity. All of the adenocarcinoma samples were collected from the GEJ or lower esophagus and ranged from well differentiated (WD) to poorly differentiated (PD), Stages I--IV, with a mix of intestinal‐ and diffuse‐type tumors. RNA was purified from all samples using an RNeasy Kit. Single‐stranded cDNA was generated using an Advantage™ RT‐for‐PCR Kit (Clontech, Palo Alto, CA). qRT‐PCR was performed using an iCycler (BioRad, Hercules, CA) with SYBR Green technology, and the threshold cycle numbers were calculated using iCycler software v3.0. Reactions were performed in triplicate and threshold cycle numbers were averaged. For validation of SAGE results, we designed gene‐specific primers for human *ANPEP*, *ECGF1*, *PP1201*, *EIF5A1*, *GKN1*, and *HPRT1*. These primers were obtained from Integrated DNA Technologies (IDT, Coralville, IA) and their sequences are available upon request. A single‐melt curve peak was observed for each product, thus confirming the purity of all amplified cDNA products. The qRT‐PCR results were normalized to *HPRT1*, which had minimal variation in all normal and neoplastic samples tested. Fold overexpression was calculated according to the formula, ![](GCC-46-914-e001.jpg "equation image"), as described earlier (Buckhaults et al., [2001](#bib8){ref-type="ref"}; El‐Rifai et al., [2002](#bib15){ref-type="ref"}) where *R* ~t~ is the threshold cycle number for the reference gene observed in the tumor, *E* ~t~ is the threshold cycle number for the experimental gene observed in the tumor, *R* ~n~ is the threshold cycle number for the reference gene observed in the normal sample, and *E* ~n~ is the threshold cycle number for the experimental gene observed in the normal sample. *R* ~n~ and *E* ~n~ values were averages of the corresponding normal analyzed samples. The relative fold expression with standard error of mean (±SEM) is shown in Figure [2](#fig2){ref-type="fig"}.

Immunohistochemistry {#sec2-3}
--------------------

Immunohistochemical (IHC) analysis of ANPEP protein expression was performed on a tumor tissue microarray (TMA) that contained 65 adenocarcinomas. Samples from adjacent normal and dysplastic tissues were included when available. All tissue samples were histologically verified, and representative regions were selected for inclusion in the TMA. All of the adenocarcinoma samples were collected from either the GEJ or lower esophagus and ranged from WD to PD, Stages I--IV, with a mix of intestinal‐ and diffuse‐type tumors. Tissue cores with a diameter of 0.5 mm were retrieved from the selected regions of the donor blocks and punched to the recipient block using a manual tissue array instrument (Beecher Instruments, Silver Spring, MD). Each tissue sample was represented by four tissue cores on the TMA. Sections (5 μm) were transferred to polylysine‐coated slides (SuperFrostPlus, Menzel‐Gläser, Braunschweig, Germany) and incubated at 37°C for 2 hr. The resulting TMA was used for IHC analysis utilizing a 1:50 dilution of ANPEP antibody (CD13/aminopeptidase‐N Ab‐3 mouse monoclonal antibody; Lab Vision Corporation, Fremont, CA). Sections were deparaffinized and rehydrated. TMA slides were treated in a microwave with citrate buffer for 20 min and incubated with the antibody at room temperature. Detection was performed using an avidin--biotin immunoperoxidase assay. Cores with no evidence of staining, or only rare scattered positive cells less than 3%, were recorded as negative. The overall intensity of staining was recorded as that for the core with the strongest intensity. IHC results were evaluated for intensity and frequency of staining. The intensity of staining was graded as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The frequency was graded from 0 to 4 by percentage of positive cells as follows: Grade 0, \<3%; Grade 1, 3--25%; Grade 2, 25--50%; Grade 3, 50--75%; Grade 4, \>75%. The index score was the product of multiplication of the intensity and frequency grades, which was then classified into a 4‐point scale: index score 0 = product of 0, index score 1 = products 1 and 2, index score 2 = products 3 and 4, index score 3 = products 6 through 12.

RESULTS {#sec1-3}
=======

Sequence Analyses of SAGE Libraries {#sec2-4}
-----------------------------------

Sequence analyses of 20,000 clones from eight SAGE libraries produced 457,894 expressed tags, with 32,035 tags (6.9%) accounting for singleton tags. The four tumor SAGE libraries (GSM758, GSM757, HG7, and HS29) produced 287,219 tags with an average of 71,804 tags per library. The normal samples (GSM14780, GSM784, 13S, and 14S) produced 170,675 tags with an average of 42,669 tags per library. The comparison of expressed tags to the UniGene cluster release of May 2005 identified 67,200 unique SAGE tags. These tags represented 16,040 known gene symbols according to UniGene information. Of these, 568 unique tags were differentially expressed between BAs and normal tissue samples (at least twofolds and *P* ≤ 0.05). These unique tags matched 395 known genes (242 upregulated and 153 downregulated) that regulate diverse cellular functions and signaling pathways, which may prove to be quite significant in the detection and prevention of cancer. Ninety‐three genes were significantly altered, showing a greater than fivefold expression change in at least two tumor libraries as compared to all four normal libraries (*P* ≤ 0.01) (Table [1](#tbl1){ref-type="table"}). Forty‐eight genes showed up‐regulation, whereas 45 were down‐regulated. The group of over‐expressed genes contained several with known cancer‐related functions, including members of S100A calcium‐binding proteins, heat‐shock protein 27 kDa (*HSB1*), heat‐shock 90 kDa protein beta (*HSPCB)*, prothymosin (*PTMA*), transmembrane bax inhibitor motif containing‐1 (*PP1201*), peroxiredoxin‐3 (*PRDX3*), and endothelial growth factor‐1 (*ECGF1*). Down‐regulated transcripts included genes such as gastrokine (*GKN1*), down‐regulated in gastric cancer (*GDDR*), gastric intrinsic factor (*GIF*), methyl‐CpG binding domain protein 3 (*MBD3*), and trefoil factor 2 (*TFF2*). CGAP maintains the public SAGE database for gene expression in human cancer (Lal et al., [1999](#bib30){ref-type="ref"}), and sequence data are publicly available at <http://www.ncbi.nih.gov/geo> and <http://cgap.nci.nih.gov/SAGE/>.

###### 

TheTop 93 Deregulated Genes in Barrett\'s Adenocarcinomas

  Tag sequence            UniGene cluster ID   Gene symbol   Title                                                                Location       T4 tag count   N4 tag count   Ratio, T4/N4   *P* value
  ----------------------- -------------------- ------------- -------------------------------------------------------------------- -------------- -------------- -------------- -------------- -----------
  *Upregulated genes*                                                                                                                                                                         
  GTGGCCACGG              Hs.112405            S100A9        S100 calcium binding protein A9                                      1q21           355            0              418            ≤0.001
  GAGCAGCGCC              Hs.112408            S100A7        S100 calcium binding protein A7                                      1q21           95             0              112            ≤0.001
  AAGATTGGTG              Hs.114286            CD9           CD9 antigen (p24)                                                    12p13.3        112            7              10             ≤0.001
  GCACCTGTCG              Hs.1239              ANPEP         Alanyl (membrane) aminopeptidase                                     15q25‐q26      76             0              89             ≤0.001
  GTGACAGAAG              Hs.129673            EIF4A1        Eukaryotic translation initiation factor 4A, isoform 1               17p13          92             4              14             ≤0.001
  TTTCCTGCTC              Hs.139322            SPRR3         Small proline‐rich protein 3                                         1q21‐q22       308            0              362            ≤0.001
  GTTCAAGTGA              Hs.186810            REPS2         RALBP1 associated Eps domain containing 2                            Xp22.2         107            2              32             ≤0.001
  ACTGTATTTT              Hs.194691            Hs.194691     G protein‐coupled receptor, family C, group 5, member A              12p13‐p12.3    103            6              10             ≤0.001
  TGGATCCTGA              Hs.302145            HBG2          Hemoglobin, gamma G                                                  11p15.5        75             0              88             ≤0.001
  CAGGAGGAGT              Hs.308709            GRP58         Protein disulfide isomerase family A, member 3                       15q15          81             2              24             ≤0.001
  CTAGTCTTTG              Hs.353175            AGPAT4        1‐acylglycerol‐3‐phosphate *O*‐acyltransferase 4                     6q26           85             0              100            ≤0.001
  TCACCCAGGG              Hs.391464            ABCC1         ATP‐binding cassette, subfamily C member 1                           16p13.1        52             0              61             ≤0.001
  CCTGGTCCCA              Hs.411501            KRT7          Keratin 7                                                            12q12‐q13      179            1              106            ≤0.001
  TTCTTTCTAA              Hs.411925            TMEM38B       Transmembrane protein 38B                                            9q31.2         58             1              34             ≤0.001
  TACCTGCAGA              Hs.416073            S100A8        S100 calcium binding protein A8                                      1q21           343            1              204            ≤0.001
  CAGCAGAAGC              Hs.424126            SERF2         Small EDRK‐rich factor 2                                             15q15.3        79             4              12             ≤0.001
  GCGGCGGATG              Hs.445351            LGALS1        Lectin, galactoside‐binding, soluble, 1                              22q13.1        89             0              105            ≤0.001
  GAACATTGCA              Hs.447579            LOC339290     Hypothetical protein LOC339290                                       18p11.31       95             0              112            ≤0.001
  GTTTGGGTTG              Hs.459927            PTMA          Prothymosin, alpha (gene sequence 28)                                2q35‐q36       162            9              11             ≤0.001
  TCACCCACAC              Hs.462859            SCFD2         Short‐chain dehydrogenase/reductase                                  17q12          337            31             6              ≤0.001
  CCCCCGCGGA              Hs.466507            LISCH7        Liver‐specific bHLH‐Zip transcription factor                         19q13.12       48             0              56             ≤0.001
  CGGAGACCCT              Hs.473583            NSEP1         Y box binding protein 1                                              1p34           76             2              23             ≤0.001
  GCCGGGTGGG              Hs.501293            BSG           Basigin (OK blood group)                                             19p13.3        77             4              11             ≤0.001
  GATACTTGGA              Hs.501911            GALNTL4       Casein kinase 2, alpha 1 polypeptide                                 11p15.3        94             0              111            ≤0.001
  ACAGGCTACG              Hs.503998            TAGLN         Transgelin                                                           11q23.2        71             3              14             ≤0.001
  GTGGCTCACA              Hs.504820            MGC14817      Hypothetical protein MGC14817                                        12q14.3        242            16             9              ≤0.001
  TAATTTTTGC              Hs.508113            OLFM4         Olfactomedin 4                                                       13q14.3        228            1              136            ≤0.001
  GTGAGCCCAT              Hs.509736            HSPCB         Heat shock 90 kDa protein 1, beta                                    6p12           149            13             7              ≤0.001
  TGTCAGTCTG              Hs.512350            Hs.512350     LOC440676                                                            1q21.1         108            1              64             ≤0.001
  AGTGCAGGGC              Hs.512488            Hs.512488     Similar to 60S ribosomal protein L10                                 12q21.2        98             1              58             ≤0.001
  GCGACCGTCA              Hs.513490            ALDOA         Aldolase A, fructose‐bisphosphate                                    16q22‐q24      206            4              31             ≤0.001
  ACCGCCGTGG              Hs.513803            CYBA          Cytochrome b‐245, alpha polypeptide                                  16q24          77             0              91             ≤0.001
  AGCAGGAGCA              Hs.515714            S100A16       S100 calcium binding protein A16                                     1q21           61             0              72             ≤0.001
  GATCTCTTGG              Hs.516484            S100A2        S100 calcium binding protein A2                                      1q21           61             0              72             ≤0.001
  ATCGTGGCGG              Hs.520942            CLDN4         Claudin 4                                                            7q11.23        62             0              73             ≤0.001
  CCCAAGCTAG              Hs.520973            HSPB1         Heat shock 27 kDa protein 1                                          7q11.23        175            7              15             ≤0.001
  AACATTCGCA              Hs.523302            PRDX3         Peroxiredoxin 3                                                      10q25‐q26      46             0              54             ≤0.001
  CTTCTCATCT              Hs.531719            ADCYAP1       Adenylate cyclase activating polypeptide 1                           18p11          85             1              51             ≤0.001
  AACTGAGGGG              Hs.5333              KIAA0711      Kelch repeat and BTB (POZ) domain containing 11                      8p23.3         94             0              111            ≤0.001
  GACTCTTCAG              Hs.534293            SERPINA3      Serpin peptidase inhibitor, clade A member 3                         14q32.1        125            1              74             ≤0.001
  CATCGCCAGT              Hs.54483             NMI           N‐myc (and STAT) interactor                                          2p24.3‐q21.3   285            0              335            ≤0.001
  GACGGCGCAG              Hs.546251            ECGF1         Endothelial cell growth factor 1                                     22q13          46             0              54             ≤0.001
  TAGCTTTAAA              Hs.554202            SVIL          Supervillin                                                          10p11.2        210            0              247            ≤0.001
  TGGCCATCTG              Hs.555971            PP1201        Transmembrane BAX inhibitor motif containing 1                       2p24.3‐p24.1   90             1              54             ≤0.001
  CTATCCTCTC              Hs.75227             NDUFA9        NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39 kDa        12p13.3        51             0              60             ≤0.001
  ACTGCCCGCT              Hs.81071             ECM1          Extracellular matrix protein 1                                       1q21           77             1              46             ≤0.001
  *Downregulated genes*                                                                                                                                                                       
  GAGAACCACT              Hs.110014            GIF           Gastric intrinsic factor (vitamin B synthesis)                       11q13          0              87             0.010          ≤0.001
  TTGCCCCTAC              Hs.128814            CHIA          Chitinase, acidic                                                    1p13.1‐p21.3   7              185            0.020          ≤0.001
  ACACAGCAAG              Hs.131603            Hs.476965     EMI domain containing 2                                              7q22.1         44             250            0.100          ≤0.001
  ACCCTCCCCA              Hs.132087            FLJ46299      Kelch domain containing 6                                            3q21.3         0              35             0.024          ≤0.001
  AACCTCCCCG              Hs.132858            RAP1GDS1      RAP1, GTP‐GDP dissociation stimulator 1                              4q23‐q25       0              33             0.026          ≤0.001
  CAGTGCCTCT              Hs.133539            MAST4         Microtubule associated serine/threonine kinase family member 4       5q12.3         1              51             0.010          ≤0.001
  AACCTCCCAC              Hs.134074            ARL2BP        Solute carrier family 35, member E1                                  19p13.11       1              42             0.010          ≤0.001
  CTGGCCCTCG              Hs.162807            TFF1          Trefoil factor 1                                                     21q22.3        95             174            0.3            ≤0.001
  TTTAGGATGA              Hs.16757             GDDR          Down‐regulated in gastric cancer GDDR                                2p13.3         5              474            0.010          ≤0.001
  CACCCCTGAT              Hs.173724            CKB           Creatine kinase, brain                                               14q32          9              74             0.070          ≤0.001
  GACCTCCCCA              Hs.178728            MBD3          Methyl‐CpG binding domain protein 3                                  19p13.3        2              64             0.020          ≤0.001
  AGTGCTCTTC              Hs.1867              PGC           Progastricsin (pepsinogen C)                                         6p21.3‐p21.1   36             595            0.040          ≤0.001
  CCATTCTGAA              Hs.209217            ASTN2         Astrotactin 2                                                        9q33.1         0              24             0.035          ≤0.001
  CAGTGCTTCC              Hs.220864            CHD2          Chromodomain helicase DNA binding protein 2                          15q26          5              41             0.070          ≤0.001
  GCTGGAGGAA              Hs.2681              GAS           Gastrin                                                              17q21          0              100            0.009          ≤0.001
  CACCTCCCCA              Hs.283739            BE614337      Ubiquilin 4                                                          1q21           4              76             0.030          ≤0.001
  AGCCTCCCCA              Hs.2859              OPRL1         Opiate receptor‐like 1                                               20q13.33       2              68             0.020          ≤0.001
  AAATCCTGGG              Hs.2979              TFF2          Trefoil factor 2 (spasmolytic protein 1)                             21q22.3        62             1086           0.030          ≤0.001
  GCAGGCTCCA              Hs.302131            GHRL          Ghrelin precursor                                                    3p26‐p25       5              50             0.060          ≤0.001
  TGCCAATTAA              Hs.307835            PGM5          Phosphoglucomutase 5                                                 9p12‐q12       6              40             0.090          ≤0.001
  CCCTGGAAGC              Hs.309288            CUGBP2        CUG triplet repeat, RNA binding protein 2                            10p13          1              33             0.020          ≤0.001
  CTGACTGTGC              Hs.36992             ATP4A         ATPase, H^+^/K^+^ exchanging, alpha polypeptide                      19q13.1        10             384            0.020          ≤0.001
  GTTTGCTTGC              Hs.370480            ABCB7         ATP‐binding cassette, sub‐family B (MDR/TAP), member 7               Xq12‐q13       1              26             0.020          ≤0.001
  AACCTCCTCA              Hs.386698            C10orf27      Chromosome 10 open reading frame 27                                  10q22.1        0              29             0.029          ≤0.001
  TATATCAGTG              Hs.388654            ATP6V1G1      ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G isoform 1    9q32           3              48             0.040          ≤0.001
  AACCTCCCCA              Hs.432854            PGA5          Porin, putative                                                      11q13          365            6637           0.030          ≤0.001
  GGAACGCAAG              Hs.434202            ATP4B         ATPase, H+/K+ exchanging, beta polypeptide                           13q34          4              138            0.020          ≤0.001
  TCTCCATACC              Hs.438454            FBXO25        F‐box protein 25                                                     8p23.3         12             376            0.020          ≤0.001
  TCCCTTTAAG              Hs.438824            CKIP‐1        CK2 interacting protein 1                                            1q21.2         3              49             0.040          ≤0.001
  TTTTTCAAGA              Hs.445586            UNQ473        DMC                                                                  19q13.2        2              35             0.030          ≤0.001
  CAGTGCTCTT              Hs.445680            Hs.445680     Similar to anaphase promoting complex subunit 1                      2q12.3         1              42             0.010          ≤0.001
  ACTGATCTGC              Hs.447547            VPS35         Hypothetical protein MGC34800                                        16q12          5              34             0.090          ≤0.001
  TCATTTTGAA              Hs.464472            MRCL3         Myosin regulatory light chain MRLC2                                  18p11.31       0              27             0.031          ≤0.001
  CAATGCTTCT              Hs.474751            MYH9          Myosin, heavy polypeptide 9, nonmuscle                               22q13.1        2              70             0.020          ≤0.001
  TGCGAGACCA              Hs.490038            CPA2          Carboxypeptidase A2 (pancreatic)                                     7q32           0              24             0.035          ≤0.001
  CATTGCTTCT              Hs.516297            TCF7L1        Transcription factor 7‐like 1 (T‐cell specific, HMG‐box)             2p11.2         0              82             0.010          ≤0.001
  CAGTGTTCTT              Hs.518611            TBC1D14       TBC1 domain family, member 14                                        4p16.1         2              29             0.040          ≤0.001
  AATGTACCAA              Hs.523130            LIPF          Lipase, gastric                                                      10q23.31       1              51             0.010          ≤0.001
  CAGTGCTTCT              Hs.527922            DLEU1         Deleted in lymphocytic leukemia, 1                                   13q14.3        349            8046           0.020          ≤0.001
  ACCTCCCCAC              Hs.529117            CYP2B7P1      Cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1   19q13.2        1              41             0.010          ≤0.001
  CAGTGCTTTT              Hs.551178            Hs.551178     CDNA FLJ46627 fis, clone TRACH2010272                                               1              60             0.010          ≤0.001
  GAGATTATGT              Hs.551521            KCNE2         Potassium voltage‐gated channel, Isk‐related family, member 2        21q22.12       5              55             0.050          ≤0.001
  TGTACCTCAG              Hs.558365            ORM2          Orosomucoid 2                                                        9q32           1              25             0.020          ≤0.001
  TCATTCTGAA              Hs.69319             GKN1          Gastrokine 1                                                         2p13.3         51             3592           0.010          ≤0.001
  AATGTCCCCA              Hs.76253             ATXN2         Ataxin 2                                                             12q24.1        2              37             0.030          ≤0.001
  TTAACCCCTC              Hs.78224             RNASE1        Ribonuclease, RNase A family, 1 (pancreatic)                         14q11.2        26             219            0.070          ≤0.001

T4, tag number in all tumor samples tested; N4, tag number in all normal samples. The expression of all genes was significantly altered in at least three tumor samples (*P* ≤ 0.05), as compared to all normal samples. At least two tumors showed more than fivefold change (*P* ≤ 0.01). Tags with "0" value were replaced with arbitrary 0.5 values for relative calculation of fold expression. The ratio was calculated after normalization to total tag numbers.
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Transcriptional Oncogenomic Hot Spots and Functional Classification of Genes {#sec2-5}
----------------------------------------------------------------------------

Onto‐Express online software (<http://vortex.cs.wayne.edu/index.htm>) (Khatri et al., [2002](#bib28){ref-type="ref"}; Draghici et al., [2003](#bib14){ref-type="ref"}) was used to identify potential transcriptional oncogenomic hot spots in the genome and obtain the functional classification of the deregulated genes. We mapped all SAGE unique transcripts (16,040 gene symbols) to their corresponding cytogenetic locations. The altered transcripts (395 known gene symbols) were analyzed against all transcripts to generate an expression ideogram and identify transcription hotspots (Fig. [1](#fig1){ref-type="fig"}). Interestingly, the distribution of altered genes was not uniform along the human chromosomes. Overexpressed genes tended to cluster in well‐defined hot spots across the human genome (Table [2](#tbl2){ref-type="table"}). For example, 26 overexpressed genes mapped to chromosome 19, of which 18 mapped to the single chromosome band 19q13. Similarly, 35 genes mapped to chromosome 1, of which 13 mapped to the chromosome band 1q21. Table [3](#tbl3){ref-type="table"} and Figure [1](#fig1){ref-type="fig"} summarize these data and map the genes to their corresponding cytogenetic locations.

![Chromosomal localization of deregulated genes. Chromosomal regions that contain up‐regulated genes are shown in red, whereas those that contain down‐regulated genes are displayed in green. Regions which contain both up‐ and down‐regulated genes are colored in yellow. The distribution of these genes did not follow a random distribution pattern and several genomic regions contain clusters of deregulated genes. Some of the more significant "hot spots" can be seen here on chromosomes 1 (*P* = 0.01), 3 (*P* = 0.02), 12 (*P* = 0.01), 15 (*P* = 0.01), and 19 (*P* = 0.01).](GCC-46-914-g004){#fig1}

###### 

Chromosomal Minimal Common Overlapping Regions of Transcription Hot Spots

  Minimal common overlapping regions   Number of genes   Gene symbols
  ------------------------------------ ----------------- ------------------------------------------------------------------------------------------------------
  *Overexpressed genes*                                  
  1q21                                 13                S100A16, S100A2, S100A7, S100A9, S100A8, ECM1, S100A10, S100A6, LMNA, SPRR3, HDGF, HIST2H2BE, TAGLN2
  6p21                                 6                 HSPA1A, HLA‐A, HSPA1B, HLA‐C, RPL10A, CLIC1
  8q24‐qter                            4                 AW103351, LY6D, LY6E, FLJ32440
  11q13                                4                 FTH1, CCND1, DKFZP761E198, TNCRNA
  12p13                                9                 GAPD, C1R, C1S, PHB2, MLF2, PTMS, FLJ22662, NDUFA9, CD9
  14q32.3                              4                 CRIP2, C14ORF173, CRIP1, IGHG1
  17q21                                4                 KRT17, PPP1R1B, GRN, COL1A1
  17q25                                4                 LGALS3BP, MRPL12, ACTG1, NT5C
  19q13.4                              5                 RPS9, RPS5, LENG8, CDC42EP5, Hs.534672
  20q13                                5                 PI3, PPGB, TMEPAI, C20ORF149, GATA5
  22q13                                7                 RPL3, Hs.102336, CDC42EP1, LGALS1, ATXN10, PLXNB2, ECGF1
  *Downregulated genes*                                  
  4q21                                 4                 IGJ, CCNI, SEC31L1, CDS1
  19q13.1                              4                 UNQ473, CYP2B7P1, FCGBP, ATP4A
  21q22                                4                 KCNE2, CLIC6, TFF1, TFF2
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###### 

Chromosomal Location of Frequent Gene Alterations in Barrett\'s Adenocarcinomas

  Chromosome   Upregulated transcripts = 242   Downregulated transcripts = 153   Grand total                                               
  ------------ ------------------------------- --------------------------------- ----------------------------------- ---- ---- ----------- ----
  1            15                              20                                35 (0.01)[a](#fn1){ref-type="fn"}   10   11   21 (0.35)   56
  2            7                               10                                17 (0.2)                            4    8    12 (0.39)   29
  3            3                               4                                 7 (0.13)                            1    2    3 (0.06)    10
  4            1                               4                                 5 (0.1)                             3    8    11 (0.02)   16
  5            0                               8                                 8 (0.26)                            2    4    6 (0.4)     14
  6            8                               2                                 10 (0.38)                           3    1    4 (0.2)     14
  7            3                               3                                 6 (0.08)                            3    5    8 (0.12)    14
  8            2                               6                                 8 (0.27)                            2    3    5 (0.37)    13
  9            1                               7                                 8 (0.46)                            0    8    8 (0.29)    16
  10           5                               7                                 12 (0.27)                           3    6    9 (0.28)    21
  11           5                               9                                 14 (0.3)                            1    5    6 (0.11)    20
  12           10                              11                                21 (0.01)                           1    8    9 (0.04)    30
  13           NA                              3                                 3 (0.36)                            NA   2    2 (0.24)    5
  14           NA                              10                                10 (0.27)                           NA   4    4 (0.17)    14
  15           NA                              8                                 8 (0.01)                            NA   5    5 (0.19)    13
  16           3                               3                                 6 (0.11)                            2    4    6 (0.07)    12
  17           4                               8                                 12 (0.3)                            1    5    6 (0.22)    18
  18           4                               0                                 4 (0.3)                             1    0    1 (0.44)    5
  19           8                               18                                26 (0.01)                           3    4    7 (0.37)    33
  20           1                               8                                 9 (0.26)                            2    3    5 (0.41)    14
  21           NA                              2                                 2 (0.23)                            NA   4    4 (0.05)    6
  22           NA                              8                                 8 (0.45)                            NA   2    2 (0.2)     10
  X            2                               1                                 3 (0.07)                            4    5    9 (0.08)    12
  Y            0                               0                                 NA                                  NA   0    NA          0

A total of 568 transcripts were up‐ or down‐regulated with statistical significance in which 395 known gene symbols were identified. In order to investigate and find statistically significant hot spots, the location of altered genes was compared with the list of all genes that are transcribed in both tumor and normal samples. The analysis was performed using Onto‐Express online software (<http://vortex.cs.wayne.edu/index.htm>).

Values in parentheses are *P* values.
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Gene ontology (GO) terms are organized in three general categories: biological process, cellular role, and molecular function; terms within each GO category are linked in defined parent--child relationships that reflect current biological knowledge (Ashburner et al., [2000](#bib2){ref-type="ref"}). Among the 395 differentially expressed genes, the number corresponding to each category was tallied and compared with the number expected for each GO category based on its representation on the reference gene list, which contained all of the unique 16,040 known gene symbols detected by analysis of the eight SAGE libraries. Significant differences from the expected were calculated with a two‐sided binomial distribution. False discovery rates (Benjamini et al., [2001](#bib5){ref-type="ref"}) and Bonferroni adjustments were also calculated. The biological meaning of the *P* values obtained depends upon the list of genes that are submitted; as our gene list is from a comparison of BA samples, it can be inferred that this cancer stimulates the processes involved within the functional groups that were most highly represented in the results of the GO classification. In our set of differentially expressed genes, the functional groups demonstrating the most significant representation appear under the biological‐process ontology and map to the cell‐cycle regulation, DNA binding and regulation, cell--environment interaction, and cell‐signaling categories. Table [4](#tbl4){ref-type="table"} summarizes several important GO functional classes.

###### 

Functional Classification of Deregulated Genes in Barrett\'s Related Adenocarcinomas Using Gene Ontology (GO)

  Gene symbol                                             Ratio   Gene symbol   Ratio    Gene symbol   Ratio    Gene symbol   Ratio
  ------------------------------------------------------- ------- ------------- -------- ------------- -------- ------------- --------
  Cell cycle regulation[a](#fn3){ref-type="fn"}                                                                               
   ALS2CR19                                               0.13    DUSP6         27.38    IGFBP7        3.14     PTMA          10.71
   AURKAIP1                                               27.38   EMP1          10.27    ILK           27.38    PTMS          6.19
   CRIP1                                                  4.17    GKN1          0.01     LGALS1        105.95   S100A6        3.83
   BTG1                                                   0.31    GRN           4.63     MACF1         6.07     SFN           42.86
   CCND1                                                  32.14   HDGF          33.33    MDK           10.12    TIMP1         9.97
   CDKN2A                                                 27.38   HIF3A         5.21     MTSS1         0.17     TM4SF4        11.31
   CHEK1                                                  4.03    IFITM1        23.21    PPP2R1B       23.21    TSPAN1        0.01
  DNA binding and replication[b](#fn4){ref-type="fn"}                                                                         
   ABCB7                                                  0.02    CTGF          22.62    HIST2H2BE     28.57    PTMS          6.19
   ABCC1                                                  61.9    CUGBP2        0.02     HSPA1B        11.61    RAB40C        71.43
   ACTA1                                                  20.24   DUT           0.04     ILK           27.38    RBM17         0.09
   ACTB                                                   4.5     ECGF1         54.76    MAST4         0.01     RHOD          26.19
   ACTG1                                                  3.06    EEF2K         0.03     MBD3          0.02     ROD1          28.57
   ARF1                                                   28.57   EIF5A         8.52     MYH9          0.02     SERPINA3      74.4
   ATP1A1                                                 14.05   ELF3          38.1     NCL           25       SET           0.29
   ATP4A                                                  0.02    ENO1          9.23     NT5C          2.52     WNK1          0.02
   PTBP1                                                  0.23    EPHA4         0.03     OBFC2A        0.23     YBX1          22.62
   CDKN2A                                                 27.38   GNAI2         15.18    PFKP          8.23     ZFHX1B        0.26
   CHD2                                                   0.07    GNAS          0.02     PPP2R1B       23.21    ZNF480        30.95
   CHEK1                                                  4.03    HDLBP         28.57                                         
  RNA binding[c](#fn5){ref-type="fn"}                                                                                         
   CUGBP2                                                 0.02    NCL           25       RNASE1        0.07     RPS5          3.07
   EIF1AX                                                 0.16    PTBP1         0.23     ROD1          28.57    SERBP1        4.32
   HDLBP                                                  28.57   RBM17         0.09     RPL18         5.7      SNRPB         9.33
   MRPL12                                                 15.48   RBM19         0.03     RPL3          21.73    YBX1          22.62
  Transcription[d](#fn6){ref-type="fn"}                                                                                       
   ZFHX1B                                                 0.26    FOXA2         0.11     NT5C          2.52     RPLP0         19.05
   ZFP36L1                                                41.67   FOXD4L1       32.14    CDKN2A        27.38    EIF3S1        28.57
   ELF3                                                   38.1    LASS6         0.16     NMI           339.29   HSPB1         14.88
   EEF1B2                                                 0.37    RAI17         25       PTBP1         0.23     BTG1          0.31
   AES                                                    3.79    TCF7L1        0        ROD1          28.57    PPP2R1B       23.21
   ENO1                                                   9.23    TIMELESS      0.36     SNRPB         9.33     ESRRG         0.05
   HIF3A                                                  5.21    YBX1          22.62    HSPA1B        11.61    PCBD2         0.36
   MBD3                                                   0.02    ZNF480        30.95    EIF1AX        0.16     GATA5         48.81
   PHB2                                                   9.33    CHD2          0.07     EIF5A         8.52                   
   PTMA                                                   10.71   JUND          12.2     EEF2K         0.03                   
  Receptor related[e](#fn7){ref-type="fn"}                                                                                    
   ANPEP                                                  90.48   F3            19.05    INTS6                  PHB2          9.33
   ANXA1                                                  4.6     GNB2L1        34.52    ITGB1         4.84     PLXNB2        8.81
   ARF1                                                   28.57   GPR68         0.16     LGALS3BP      47.62    SLAMF7        46.43
   OPRL1                                                  0.02    HSPA1A        55.95    LRP1B         38.1                   
   DRD5                                                   0.02    IFITM1        23.21    MTSS1         0.17                   
   EPHA4                                                  0.03    IL6ST         4.06                                          
  Calcium ion binding[f](#fn8){ref-type="fn"}                                                                                 
   ACTN4                                                  10      EEF2K         0.03     MRLC2         3.71     S100A7        113.1
   ANXA1                                                  4.6     EFHD2         11.31    PADI1         42.86    S100A8        204.17
   ANXA10                                                 0.24    ITGB1         4.84     PRKCSH        29.76    S100A9        422.62
   ANXA11                                                 16.67   ITPR3         0.22     REPS2         31.85    SPARC         4.31
   C1R                                                    24.4    LRP1B         38.1     S100A10       4.16     SVIL          250
   C1S                                                    19.05   MACF1         6.07     S100A16       72.62    TKT           35.71
   CLTB                                                   10.32   MMP11         14.58    S100A2        72.62    VMD2L3        27.38
   CSPG2                                                  27.38   MRCL3         4.76     S100A6        3.83                   
  Zinc ion binding[g](#fn9){ref-type="fn"}                                                                                    
   ALPPL2                                                 34.52   CRIP2         25       MMP11         14.58    S100A7        113.1
   ANPEP                                                  90.48   ESRRG         0.05     MT1F          0.17     TRIM2         0.18
   RAI17                                                  25      GATA5         48.81    PARK2         0.02     ZFHX1B        0.26
   CA2                                                    0.26    GIT2          27.38    PDLIM1        15.48    ZFP36L1       41.67
   CPA2                                                   0.01    HERC2         36.9     PDLIM7        46.43    ZNF480        30.95
   CRIP1                                                  4.17    HINT1         24.4                                          
  Cell signaling[h](#fn10){ref-type="fn"}                                                                                     
   ADCYAP1                                                50.6    EPHA4         0.03     IL6ST         4.06     PDIA3         24.12
   ANXA1                                                  4.6     FKBP8         41.67    ILK           27.38    PPP1R1B       40.48
   ARF1                                                   28.57   FMOD          0.17     ITGB1         4.84     PRKCSH        29.76
   WNT4                                                   0.03    GAST          0        ITPR3         0.22     PRMT1         30.95
   BSG                                                    11.46   GHRL          0.06     LGALS3BP      47.62    PYCR2         47.62
   BTRC                                                   7.54    GNAS          0.02     LY6E          7.29     RAB40C        71.43
   C1S                                                    19.05   GNB2L1        34.52    MDK           10.12    REPS2         31.85
   C9orf86                                                25      GPR68         0.164    MKLN1         6.45     RHOD          26.19
   CDS1                                                   0.01    GRN           4.63     MTSS1         0.17     SFN           42.86
   CEACAM6                                                8.57    HDGF          33.33    MYH9          0.02     SNX6          34.52
   DRD5                                                   0.02    HINT1         24.4     NMI           339.29   SPARC         4.31
   ECGF1                                                  54.76   IFITM1        23.21    OPRL1         0.02                   
  Inflammation[i](#fn11){ref-type="fn"}                                                                                       
   ANXA1                                                  4.6     LGALS3BP      47.62    PDLIM1        15.48    SERPINA3      74.4
   CYBB                                                   0.018   LY6E          7.29     PRMT1         30.95    TFF1          0.32
   GPR68                                                  0.164   MLF2          6.94     PTMS          6.19     TFF2          0.03
   GPX1                                                   9.92    NMI           339.29   S100A8        204.17                 
   IL1RN                                                  7.94    ORM2          0.024    S100A9        422.62                 
  Cell environment interaction[j](#fn12){ref-type="fn"}                                                                       
   ACTN4                                                  10      ECGF1         54.76    LY6D          45.83    S100A6        3.83
   ADCYAP1                                                50.6    EMILIN1       26.19    MDK           10.12    S100A9        422.62
   ANPEP                                                  90.48   ENAH          0.01     MKLN1         6.45     SLAMF7        46.43
   ANXA1                                                  4.6     FCGBP         0.18     MTSS1         0.17     SPON2         6.67
   BTG1                                                   0.31    GRN           4.63     PGM5          0.09     TSPAN1        0.01
   CD9                                                    9.52    IL32          17.86    PPFIBP2       0.05     WNT4          0.03
   CEACAM6                                                8.57    KLK6          35.71    PPP2R1B       23.21                  
   CTGF                                                   22.62   LGALS3BP      47.62    PYCR2         47.62                  

The average ratio is shown. This ratio was calculated by comparing the total number of tags in tumor samples and normal samples.

Examples: GO: 0007049 cell cycle, GO: 0008283 cell proliferation, and GO: 0006915 apoptosis.

Examples: GO: 0000166 nucleotide binding, GO: 0003677 DNA binding, and GO: 0006260 DNA replication.

Examples: GO: 0003723 RNA binding and GO: 0003730 mRNA 3′‐UTR binding.

Examples: GO: 0003700 transcription factor activity, GO: 0006350 transcription, and GO: 0006355 DNA dependent regulation of transcription.

Examples: GO: 0004872 receptor activity, GO: 0005102 receptor binding, and GO: 0005057 receptor signaling protein activity.

Examples: GO: 0005509 calcium ion binding.

Examples: GO: 0008270 zinc ion binding.

Examples: GO: 0007165 signal transduction, GO: 0007166 cell surface receptor linked signal transduction, and GO: 0007186 G‐protein coupled receptor protein signaling pathway.

Examples: GO: 0006952 defense response and GO: 0006954 inflammatory response.

Examples: GO: 0006928 cell motility, GO: 0007155 cell adhesion, and GO: 0007267 cell--cell signaling.
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Validation of Transcriptional Targets {#sec2-6}
-------------------------------------

To evaluate further the SAGE data, we selected five novel genes (*ANPEP*, *ECGF1*, *PP1201*, *EIF5A1*, and *GKN1*, all of which have important cellular or biological features) for validation with qRT‐PCR. We confirmed over‐expression of *ANPEP, ECGF1, PP1201*, and *EIF5A1* and down‐regulation of *GKN1* in primary GEJ and lower esophageal adenocarcinoma samples (Table [5](#tbl5){ref-type="table"}, Fig. [2](#fig2){ref-type="fig"}). Interestingly, GKN1 was not expressed in normal esophageal mucosa samples but showed a transient expression in BE samples where 4/6 of these samples demonstrated expression levels comparable to those observed in normal gastric mucosae. We did not have samples with Barrett\'s dysplasia for qRT‐PCR. The *GKN1* expression was lost in almost all adenocarcinoma samples (Fig. [2](#fig2){ref-type="fig"}). The qRT‐PCR products were run on 1.2% agarose gels for visual confirmation of these results (Fig. [3](#fig3){ref-type="fig"}). RT‐PCR results for all five genes were also compared in each individual primary tissue sample to determine any correlations in combined gene expression levels; however, we were unable to find any correlations of statistical significance.

![Quantitative real‐time reverse‐transcription PCR showing fold expression changes at the mRNA level of five representative genes. qRT‐PCR analysis was performed using iCycler on 31 lower esophageal and GEJ adenocarcinoma samples (Tu) and 6 Barrett\'s esophagus (BE) samples in comparison with 26 normal glandular mucosa samples (N). The horizontal axis shows sample numbers, whereas the fold expression in tumor samples compared with that in normal samples is shown on the vertical axis. The fold expression was calculated according to the formula: ![](GCC-46-914-e002.jpg "equation image") as detailed in the "[Materials and Methods](#sec1-2){ref-type="sec"}" section. Each bar represents one sample. The displayed mean fold expression for each sample is calculated in comparison with the expression average of the 26 normal samples. The expression of each gene was normalized to the expression of *HPRT1*, which showed minimal variation in all normal and neoplastic samples tested. *GKN1* shows downregulation (≤0.4‐fold expression) whereas *ANPEP*, *PP1201*, *EIF5A1*, and *ECGF1* demonstrate overexpression (≥2.5 fold expression) in primary tumors as compared to normal tissue samples.](GCC-46-914-g003){#fig2}

![Visualization of RT‐PCR products on gel electrophoresis. Five matched tumor and normal samples that were analyzed using qRT‐PCR were subjected to 1.2% agarose gel electrophoresis and ethidium bromide staining. The intensity of bands confirms the PCR results, indicating higher mRNA expression levels of *ANPEP, PP1201, EIF5A1*, and *ECGF*, as well as lower expression of *GKN1* in most of the tumor samples as compared with their matched normal control samples. *HPRT1* was used as a control to show similar levels in each matched normal and tumor samples.](GCC-46-914-g002){#fig3}

###### 

Summary of qRT‐PCR Results

              Overexpressed genes                  Downregulated gene                             
  ----------- ------------------------------------ -------------------- ------------ ------------ -------------
  All cases   9/31 (29)[a](#fn13){ref-type="fn"}   15/31 (48)           14/31 (45)   15/31 (48)   30/31 (97)
  Gender                                                                                          
   Male       4/19 (21)                            8/19 (42)            10/19 (53)   14/19 (74)   19/19 (100)
   Female     2/4 (50)                             3/4 (75)             1/4 (25)     1/4 (25)     4/4 (100
  3/8 (38)    4/8 (50)                             3/8 (38)             0/8 (0)      7/8 (88)     
  Site                                                                                            
   GEJ        4/10 (40)                            7/16 (44)            7/16 (44)    10/16 (63)   16/16 (100)
   ESO        3/10 (30)                            4/10 (40)            4/10 (40)    5/10 (50)    10/10 (100)
   NA         2/5 (40)                             4/5 (80)             3/5 (60)     0/5 (0)      4/5 (80)
  Stage                                                                                           
   T1--T2     2/8 (25)                             3/8 (37)             5/8 (62)     6/8 (75)     8/8 (100)
   T3--T4     5/14 (36)                            7/14 (50)            5/14 (36)    8/14 (57)    14/14 (100)
   NA         3/9 (33)                             5/9 (55)             4/9 (44)     1/9 (11)     8/9 (89)
  Grade                                                                                           
   WD‐MD      3/10 (30)                            5/10 (50)            5/10 (50)    8/10 (80)    10/10 (100)
   PD         2/9 (22)                             4/9 (44)             5/9 (56)     6/9 (67)     9/9 (100)
   NA         4/12 (33)                            6/12 (50)            4/12 (33)    1/12 (8)     11/12 (92)
  Node                                                                                            
   N0         2/8 (25)                             2/8 (25)             5/8 (63)     6/8 (75)     8/8 (100)
   N1--N2     4/13 (31)                            7/13 (54)            4/13 (31)    7/13 (54)    13/13 (100)
   N3--N4     0/0 (0)                              0/0 (0)              0/0 (0)      0/0 (0)      0/0 (0)
   NA         3/10 (30)                            6/10 (60)            5/10 (50)    2/10 (20)    9/10 (90)

Values in parentheses are percentages. NA, information not available; GEJ, gastroesophageal junction; ESO, esophageal; WD, well‐differentiated; MD, moderately‐differentiated; PD, poorly differentiated. We did not observe statistical significance with any of the correlates due to small sample size.
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Expression of ANPEP in Tumor TMA {#sec2-7}
--------------------------------

The IHC analysis demonstrated a lack of immunostaining for ANPEP in normal esophageal and gastric epithelial tissues. On the other hand, BAs showed overexpression of ANPEP (Score +1 to +3) in 35/65 (54%) tumors. A weak to moderate expression of ANPEP (Score +1 to +2) was observed in 6/7 (86%) high‐grade Barrett\'s dysplasia samples. The immunostaining pattern of ANPEP was cytoplasmic with strong extracellular and luminal expression (Fig. [4](#fig4){ref-type="fig"}). The immunostaining for ANPEP was observed in tumors with intestinal and diffuse histological subtypes and in all stages (Table [6](#tbl6){ref-type="table"}). However, the relatively small sample size did not provide a sufficient statistical power to detect significant correlations between the IHC staining patterns and clinicopathological factors such as tumor histology, grade, or stage.

![Immunohistochemical staining for ANPEP. (A, B) Normal gastric tissue glands (A) and normal esophageal squamous tissues (B) are negative for ANPEP immunostaining (Score 0). (C) Barrett\'s dysplastic tissue demonstrates immunostaining for ANPEP that is secreted in the lumen (Score +2). (D) Barrett\'s metaplasia tissue shows glandular staining (Score +2). (E) Diffuse‐type esophageal adenocarcinoma tissue shows staining for ANPEP in the cell cytoplasm with significant localization along the cell membranes (Score +3). (F) Intestinal‐type esophageal adenocarcinoma tissue showing high levels of ANPEP along the cell membranes as well as luminal secretion (Score +3). All photos (insets at upper‐right quadrant) are taken at 200× and 400× magnification.](GCC-46-914-g001){#fig4}

###### 

Summary of Immunohistochemistry Analysis of ANPEP on Tissue Microarrays

                IHC score                          Total                        
  ------------- ---------------------------------- --------- --------- -------- ----------
  All cases     30 (46)[a](#fn14){ref-type="fn"}   21 (32)   6 (9)     8 (12)   65 (100)
  Gender                                                                        
   Male         22 (73)                            16 (76)   6 (100)   7 (88)   51 (78)
   Female       2 (7)                              2 (10)    0 (0)     1 (13)   5 (8)
   NA           5 (17)                             3 (14)    0 (0)     0 (0)    8 (13)
  Site                                                                          
   GEJ          11 (37)                            8 (38)    3 (50)    6 (75)   28 (43)
   ESO          15 (50)                            11 (52)   3 (50)    2 (25)   31 (48)
   NA           3 (10)                             2 (10)    0 (0)     0 (0)    5 (8)
  Histology                                                                     
   Diffuse      10 (33)                            7 (33)    0 (0)     2 (25)   19 (29)
   Intestinal   19 (63)                            14 (67)   6 (100)   6 (75)   45 (69)
  Stage                                                                         
   T1--T2       6 (20)                             10 (48)   2 (33)    1 (13)   19 (29)
   T3--T4       15 (50)                            6 (29)    3 (50)    4 (50)   28 (43)
   NA           8 (27)                             5 (24)    1 (17)    3 (38)   17 (26)
  Grade                                                                         
   WD           3 (10)                             3 (14)    1 (17)    0 (0)    7 (11)
   MD           4 (13)                             5 (24)    2 (33)    2 (25)   13 (20)
   PD           19 (63)                            13 (62)   3 (50)    6 (75)   41 (63)
  Node                                                                          
   N0           18 (60)                            10 (48)   4 (67)    2 (25)   34 (52)
   N1--N2       3 (10)                             8 (38)    1 (17)    4 (50)   16 (25)
   N3--N4       1 (3)                              0 (0)     0 (0)     0 (0)    1 (2)
   NA           7 (23)                             3 (14)    1 (17)    2 (25)   13 (20)

NA, information not available; GEJ, gastroesophageal junction; ESO, esophageal; WD, well‐differentiated; MD, moderately‐differentiated; PD, poorly differentiated. We did not observe statistical significance with any of the correlates due to small sample size.

Values in parentheses are percentages.
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DISCUSSION {#sec1-4}
==========

In this study, we performed a comprehensive analysis of the transcriptome of BAs using SAGE. The major advantage to using SAGE is the quantitative ability to evaluate accurately transcript numbers without prior sequence information. The SAGE analysis produced a great deal of information about transcripts and candidate cancer genes, and we have interpreted these data in terms of possible genomic and functional organization of candidate cancer genes.

SAGE analysis requires laborious and extensive sequencing that often limits the number of samples that are subjected to analysis. We obtained a total of 457,894 expressed tags from eight SAGE libraries with minimal singleton tags (32,035; 6.9%). The qRT‐PCR analysis on a larger sample size confirmed the SAGE results and validated the overexpression of *ANPEP*, *ECGF1*, *PP1201*, and *EIF5A1* and downregulation of *GKN1. ECGF1* (thymidine phosphorylase) expression has been shown to correlate with the angiogenic activity of some tumors (Mazurek et al., [2006](#bib35){ref-type="ref"}). *ECGF1* expression may be a sign of tumor‐stromal interaction promoting greater vascularization around the cancer lesion and has also been found to protect cells from DNA‐damaging agents and related apoptosis (Jeung et al., [2006](#bib26){ref-type="ref"}). *EIF5A1* (eukaryotic translation factor 1) has been shown to be involved in cell proliferation through the action of polyamines (Nishimura et al., [2002](#bib40){ref-type="ref"}, [2005](#bib41){ref-type="ref"}), and plays a role in the regulation of TP53‐related apoptosis (Li et al., [2004](#bib31){ref-type="ref"}). PP1201, also known as transmembrane Bax inhibitor motif‐containing 1 (*TMBIM1*), is a novel gene of cancer cells. Although very little is known regarding *GKN1*, it has been previously reported as highly expressed in normal gastric epithelium (Martin et al., [2003](#bib34){ref-type="ref"}) and down‐regulated in gastric carcinomas (Oien et al., [2004](#bib43){ref-type="ref"}). We have detected strong expression of *GKN1* in BE that was followed with loss of its expression in adenocarcinomas. This transient expression of *GKN1* may be a protective response to acid‐induced reflux‐disease injury that is the lost with cellular progression to cancer. ANPEP, also known as CD13, is of a particular clinical interest since it is a secreted protein that may be used as a potential biomarker. Using IHC, analysis of ANPEP expression demonstrated protein expression at the outer cell membrane layers with significant secretion into the lumen of 6/7 Barrett\'s high‐grade dysplasia samples and generally greater expression in 35/65 adenocarcinomas, suggesting that ANPEP overexpression may be an early event in carcinogenesis. *ANPEP* expression plays a role in angiogenesis where a reduction in expression has been shown to cause reduced capillary formation (Fukasawa et al., [2006](#bib20){ref-type="ref"}), cell motility (Chang et al., [2005](#bib10){ref-type="ref"}), and adhesion (Fukasawa et al., [2006](#bib20){ref-type="ref"}). Inhibition of ANPEP decreases the invasive potential of metastatic tumor cells in vitro (Saiki et al., [1993](#bib49){ref-type="ref"}). Interestingly, ANPEP is also a cell‐surface metalloproteinase that acts as a receptor for human coronavirus (Yeager et al., [1992](#bib64){ref-type="ref"}) and is considered to be a marker for epithelial--mesenchymal interaction (Sorrell et al., [2003](#bib53){ref-type="ref"}).

The combination of transcriptional analysis together with cytogenetic information provided a powerful tool to align altered transcripts across the human genome. Interestingly, the distribution of deregulated genes did not follow a uniform pattern across the genome. Instead, we found a remarkable pattern of distribution with the presence of transcriptional hot spots along chromosomal domains. From this pattern, we were able to identify novel, transcriptionally active, and oncogenomic hot spots. One of our surprising findings was the clustering of 26 overexpressed genes in one of the smallest human chromosomes, 19. We also identified a number of other hot spots, such as 1q21 (13 genes), 12p13 (9 genes), and 6p21.2 (6 genes) (Table [2](#tbl2){ref-type="table"}) in a recent analysis of amplification‐based clustering demonstrated that cancers with similar etiology, cell‐of‐origin, or topographical location have a tendency to obtain convergent amplification profiles (Myllykangas et al., [2006](#bib38){ref-type="ref"}). In line with this observation, Vogel et al. ([2005](#bib61){ref-type="ref"}) reported that genes expressed in concert are organized in a linear arrangement for coordinated regulation. The present evidence suggests organization of a large proportion of the human transcriptome into gene clusters throughout the genome, which are partly regulated by the same transcription factors, share biological functions, and are characterized by nonhousekeeping genes (Vogel et al., [2005](#bib61){ref-type="ref"}). Taken together, our results further highlight the complex organization of the cancer genome and suggest that integrated analysis of the transcriptome may reveal similar findings in other tumors as well.

Each cancer candidate gene was assigned to a functional group based on GO information (Table [4](#tbl4){ref-type="table"}). Using this approach, several groups that are highly interesting and relevant to carcinogenesis were identified including transcriptional regulators (38 genes) and zinc finger transcription factors (23 genes). Similarly, several candidate genes were found to be involved in the notable functional groups of cell‐environment interaction and signal transduction. Subsets of these groups were of interest and included metalloproteinases and G proteins and their regulators. Among the interesting groups, we also observed deregulation of 31 genes that regulate cell calcium homeostasis. The role of calcium‐binding proteins in carcinogenesis has drawn a complex picture showing downregulation or overexpression depending upon the tumor type and location (Kao et al., [1990](#bib27){ref-type="ref"}; Mueller et al., [1999](#bib37){ref-type="ref"}; Heighway et al., [2002](#bib22){ref-type="ref"}; Heizmann et al., [2002](#bib23){ref-type="ref"}; Imazawa et al., [2005](#bib25){ref-type="ref"}). The SAGE data also indicated up‐regulation of several members of the protein phosphatases such as *PPAP2B*, *HIF3A*, and *PPP2R1B* that are known to regulate and activate several cellular kinases (Parsons, [1998](#bib45){ref-type="ref"}; Nigg, [2001](#bib39){ref-type="ref"}; Bakkenist and Kastan, [2004](#bib3){ref-type="ref"}; Ventura and Nebreda, [2006](#bib60){ref-type="ref"}). We have recently shown that over‐expression of *PPP1R1B* in gastrointestinal cancers is associated with several oncogenic properties including the resistance of cancer cells to drug‐induced apoptosis (Belkhiri et al., [2005](#bib4){ref-type="ref"}). Taken together, our data suggest a genomic organization of cancer genes, which are involved in the deregulation of specific cellular processes important for the tumorigenesis cascade.

In conclusion, our findings indicate the presence of transcriptionally active oncogenomic hot spots in the cancer genome of BAs. We have detected deregulation of several important cancer genes and identified novel targets for carcinogenesis. The biological functions and clinical significance of these genes will be elucidated in future studies.
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